ChemRar Group and The Russian Direct Investment Fund (RDIF) have reported positive data from a multi-centre clinical trial of Favipiravir in patients hospitalised due to Covid-19.

During the randomised, open, comparative trial, 40 patients were treated with the drug. Of these patients, 60% tested negative for coronavirus following five days of treatment, two times higher compared to those on standard therapy.

The findings are said to be consistent with data from studies performed in China, which also revealed a decrease in the disease duration from 11 days to four-five days.